The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells

Journal of Immunology

Volumn 185, Issue 10, 2010, Pages 6115-6127

  Iype, Tessy ^a   Sankarshanan, Mohan ^a   Mauldin, Ileana S ^a   Mullins, David W ^a   Lorenz, Ulrike ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; PROTEIN TYROSINE PHOSPHATASE SHP 1; STIBOGLUCONATE SODIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SRC HOMOLOGY DOMAIN;

ANIMALS; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 78650663108     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000622     Document Type: Article

References (47)

1. Tang, Q., and J. A. Bluestone. 2008. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9:239-244.
2. Shevach, E. M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30:636-645.
3. Burchill, M. A., J. Yang, C. Vogtenhuber, B. R. Blazar, and M. A. Farrar. 2007. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J. Immunol. 178:280-290.
4. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061.
5. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
6. Wing, K., Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, T. Nomura, and S. Sakaguchi. 2008. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271-275.
7. Friedline, R. H., D. S. Brown, H. Nguyen, H. Kornfeld, J. Lee, Y. Zhang, M. Appleby, S. D. Der, J. Kang, and C. A. Chambers. 2009. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J. Exp. Med. 206:421-434.
8. Bopp, T., C. Becker, M. Klein, S. Klein-Hessling, A. Palmetshofer, E. Serfling, V. Heib, M. Becker, J. Kubach, S. Schmitt, et al. 2007. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204:1303-1310.
9. Garín, M. I., C. C. Chu, D. Golshayan, E. Cernuda-Morollón, R. Wait, and R. I. Lechler. 2007. Galectin-1: a key effector of regulation mediated by CD4+ CD25+ T cells. Blood 109:2058-2065.
10. Deaglio, S., K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204:1257-1265.
11. Huang, C. T., C. J. Workman, D. Flies, X. Pan, A. L. Marson, G. Zhou, E. L. Hipkiss, S. Ravi, J. Kowalski, H. I. Levitsky, et al. 2004. Role of LAG-3 in regulatory T cells. Immunity 21:503-513.
12. Collison, L. W., C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg, and D. A. Vignali. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566-569.
13. Liu, G., S. Burns, G. Huang, K. Boyd, R. L. Proia, R. A. Flavell, and H. Chi. 2009. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat. Immunol. 10:769-777.
14. Pao, L. I., K. Badour, K. A. Siminovitch, and B. G. Neel. 2007. Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu. Rev. Immunol. 25:473-523.
15. Lorenz, U. 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol. Rev. 228:342-359.
16. Thornton, A. M., and E. M. Shevach. 2000. Suppressor effector function of CD4+ CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164:183-190.
17. Thornton, A. M., and E. M. Shevach. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287-296.
18. Hänig, J., and M. B. Lutz. 2008. Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J. Immunol. 180:1405-1413.
19. Kim, J. K., M. Klinger, J. Benjamin, Y. Xiao, D. J. Erle, D. R. Littman, and N. Killeen. 2009. Impact of the TCR signal on regulatory T cell homeostasis, function, and trafficking. PLoS ONE 4: e6580.
20. Tsui, H. W., K. A. Siminovitch, L. de Souza, and F. W. L. Tsui. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4:124-129.
21. Shultz, L. D., P. A. Schweitzer, T. V. Rajan, T. Yi, J. N. Ihle, R. J. Matthews, M. L. Thomas, and D. R. Beier. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73:1445-1454.
22. Carter, J. D., G. M. Calabrese, M. Naganuma, and U. Lorenz. 2005. Deficiency of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) causes enrichment of CD4+CD25+ regulatory T cells. J. Immunol. 174:6627-6638.
23. Pathak, M. K., and T. Yi. 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 167:3391-3397.
24. Fan, K., E. Borden, and T. Yi. 2009. Interferon-gamma is induced in human peripheral blood immune cells in vitro by sodium stibogluconate/interleukin-2 and mediates its antitumor activity in vivo. J. Interferon Cytokine Res. 19:451-460.
25. Li, J., D. J. Lindner, C. Farver, E. C. Borden, and T. Yi. 2007. Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action. Cancer Chemother. Pharmacol. 60:341-349.
26. Mahmoud, A. A., and K. S. Warren. 1977. Algorithms in the diagnosis and management of exotic diseases. XXIV. Leishmaniases. J. Infect. Dis. 136:160-163.
27. The Cleveland Clinic; National Cancer Institute. Sodium stibogluconate and interferon in treating patients with advanced solid tumors, lymphoma, or myeloma. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00311558.
28. The Cleveland Clinic; National Cancer Institute. Sodium stibogluconate and interferon alpha-2b followed by cisplatin, vinblastine, and temozolomide in treating patients with advanced melanoma or other cancer. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00498979.
29. M. D. Anderson Cancer Center; VioQuest Pharmaceuticals. Sodium stibogluconate with interferon alpha-2b for patients with advanced malignancies. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00629200.
30. Carter, J. D., B. G. Neel, and U. Lorenz. 1999. The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. Int. Immunol. 11:1999-2014.
31. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180:25-34.
32. Radu, D. L., N. Noben-Trauth, J. Hu-Li, W. E. Paul, and C. A. Bona. 2000. A targeted mutation in the IL-4Ralpha gene protects mice against autoimmune diabetes. Proc. Natl. Acad. Sci. USA 97:12700-12704.
33. Bullock, T. N., T. A. Colella, and V. H. Engelhard. 2000. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol. 164:2354-2361.
34. Lyons, A. B., and K. V. Doherty. 2004. Flow cytometric analysis of cell division by dye dilution. Curr. Protoc. Cytom. Chapter 9: Unit 9.11.
35. Sankarshanan, M., Z. Ma, T. Iype, and U. Lorenz. 2007. Identification of a novel lipid raft-targeting motif in Src homology 2-containing phosphatase 1. J. Immunol. 179:483-490.
36. Li, J., M. Bracht, X. Shang, J. Radewonuk, E. Emmell, D. E. Griswold, and L. Li. 2006. Ex vivo activated OVA specific and non-specific CD4+CD25+ regulatory T cells exhibit comparable suppression to OVA mediated T cell responses. Cell. Immunol. 241:75-84.
37. Grebe, K. M., and T. A. Potter. 2002. Enumeration, phenotyping, and identification of activation events in conjugates between T cells and antigen-presenting cells by flow cytometry. Sci. STKE 2002: pl14.
38. Fan, K., M. Zhou, M. K. Pathak, D. J. Lindner, C. Z. Altuntas, V. K. Tuohy, E. C. Borden, and T. Yi. 2005. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages. J. Immunol. 175:7003-7008.
39. Huehn, J., K. Siegmund, J. C. Lehmann, C. Siewert, U. Haubold, M. Feuerer, G. F. Debes, J. Lauber, O. Frey, G. K. Przybylski, et al. 2004. Developmental stage, phenotype, and migration distinguish naive-and effector/memory-like CD4+ regulatory T cells. J. Exp. Med. 199:303-313.
40. Siegmund, K., M. Feuerer, C. Siewert, S. Ghani, U. Haubold, A. Dankof, V. Krenn, M. P. Schön, A. Scheffold, J. B. Lowe, et al. 2005. Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood 106:3097-3104.
41. Naik, S. H. 2008. Demystifying the development of dendritic cell subtypes, a little. Immunol. Cell Biol. 86:439-452.
42. Onishi, Y., Z. Fehervari, T. Yamaguchi, and S. Sakaguchi. 2008. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. USA 105:10113-10118.
43. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502-507.
44. Suffia, I., S. K. Reckling, G. Salay, and Y. Belkaid. 2005. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J. Immunol. 174:5444-5455.
45. Szymczak-Workman, A. L., C. J. Workman, and D. A. Vignali. 2009. Cutting edge: regulatory T cells do not require stimulation through their TCR to suppress. J. Immunol. 182:5188-5192.
46. Liang, B., C. Workman, J. Lee, C. Chew, B. M. Dale, L. Colonna, M. Flores, N. Li, E. Schweighoffer, S. Greenberg, et al. 2008. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J. Immunol. 180:5916-5926.
47. Huse, M., B. F. Lillemeier, M. S. Kuhns, D. S. Chen, and M. M. Davis. 2006. T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol. 7:247-255.